What is a clinical trial?

Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention. They are the primary way that researchers find out if a new treatment, like a new drug or diet or medical device (for example, a pacemaker) is safe and effective in people. A clinical trial may also look at how to make life better for people living with a life-threatening disease or a chronic health problem. 

Why participate?

Some join a trial because the treatments they have tried for their health problem did not work. Others participate because there is no treatment for their health problem. By being part of a clinical trial, participants may find out about new treatments before they are widely available. Some studies are designed for, or include, people who are healthy but want to help find ways to prevent a disease, such as one that may be common in their family.

Who is eligible?

To join a clinical trial, you must meet the conditions of the study. If you qualify for the study, it is still your choice to join. To join, you’ll need to review and sign a paper called an informed consent form. This form describes the study in detail, including the risks and benefits. You will be able to fully read the entire form and have all your questions answered. You can also discuss joining the study with family and friends. When all your questions are answered, you may decide to sign the form and start in the study.

How do I find a Clinical Trial?

Click on a Category below to Search clinical trials by Subject or Location or you can put a word in the search box.

Clinical Trials are held in various locations around Shreveport-Bossier and in other cities. Information on the location and who to contact with questions is included in the information on each trial link below.

To evaluate the efficacy of a single dose of 150 x 106 AMDC-USR in the reduction of stress incontinence episode frequency (IEF) in adult female subjects at 12 months post-treatment.

Read More about CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence

The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body’s immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab may help prevent your cancer from returning, but it could also cause side effects. This research study will allow researchers to find out whether this different treatment is better, the same, or worse than the usual treatment for lung cancer.

Read More about Surgical Resection and Adjuvant Chemotherapy in Non Small Cell Lung Cancers

The purpose of this study is to see if adding either prochlorperazine or olanzapine to the standard antiemetic regimen of Akynzeo and dexamethasone at chemotherapy cycle 2 can improve chemotherapy-related nausea and vomiting in people who experienced it at chemotherapy cycle 1.  We also want to find out if either of these drugs is more effective than the other in controlling chemotherapy-related nausea and vomiting.

Read More about A Study to Help with Nausea Related to Chemotherapy

The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer. Some studies have suggested that aspirin may lower the risk of breast cancer coming back, but others have not, so we do not know if aspirin will help decrease breast cancer recurrence. This study will evaluate whether patients taking aspirin once per day will have a lower rate of cancer recurrence than patients taking a placebo. A placebo is a tablet that looks like the study drug (aspirin), but contains no medication.

Read More about Aspirin for Breast Cancer Study

This study is for people with superficial bladder cancer that has not invaded into the bladder muscle wall and that did not respond to Bacillus Calmette-Guerin (BCG). Unless the person is in a study, when people do not respond to BCG, or the FDA approved drug Valrubicin, or other treatments individualized to a person’s clinical situation, treatment usually involves removal of the bladder (cystectomy).   This study will test how effective the investigational drug atezolizumab is at keeping non-muscle invasive bladder cancer from coming back or getting worse. The study drug, atezolizumab, although approved by the FDA to treat other stages of bladder and lung cancers, is not approved by the FDA for treatment of bladder cancer at this early stage.

Read More about How Effective Atezolizumab is at keeping Bladder Cancer from Coming Back or Getting Worse

This study is for people who have high grade bladder cancer that has not entered the muscle.  In the U.S., people who are not in a study are usually treated with BCG LIVE (TICE® BCG) (an abbreviation for Bacillus Calmette–Guérin), which is a bacteriu.  It is given directly into the bladder and infects the bladder, BCG stimulates the immune system to fight the bladder cancer. BCG is usually tolerated well by patients with normal immune system function.

For patients who receive the usual approach for bladder cancer, about 40 out of 100 are free of cancer at five years.

Read More about Evaluating the Influence of Bacillus Calmette–Guérin (BCG) Strain Differences and T Cell Priming with Intradermal BCG

This study is being done to answer the following question:

Can we lower the chance of getting painful mouth sores by treating you with a dexamethasone mouthwash at the start of your cancer treatment?

We are doing this study to find out if this approach is better or worse than the usual approach for preventing painful mouth sores.  The usual approach is defined as care most people get for painful mouth sores.

Read More about How Well Dexamethasone Works in Reducing Everolimus-induced Oral Stomatitis (inflammation of the mouth and lips)

The purpose of this study is to learn if the HBV medicine called tenofovir alafenamide (TAF) can help reduce the chance that HBV gets worse or comes back during cancer treatment. It is not known if starting TAF  with chemotherapy is better than waiting until HBV returns or becomes more active. 

Read More about A Trial of Antiviral Therapy in Patients with Hepatitis B Virus (HBV) Infection Receiving Therapy for Solid Tumors

The purpose of this study is to look at the effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.  The addition to the usual chemotherapy could prevent your cancer from returning, but it could also cause side effects.  This study will allow the researchers to know whether giving carboplatin with the usual chemotherapy is better, the same, or worse than giving the usual chemotherapy. 

Read More about Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Treatment of Breast Cancer

This is a Phase 2, multicenter, randomized, active-controlled, open-label study with a 3-arm parallel design. It is planned to be conducted at investigator sites in the United States, with other countries to be considered. Approximately 690 infants aged ³42 to £98 days will be randomized (1:1:1) to receive a vaccine series with:

· c7vPnC coadministered with Prevnar 13 (Group 1 - coadministration);

· c7vPnC given 1 month after Prevnar 13 (Group 2 - staggered administration); or

· Prevnar 13 alone as the active control group (Group 3 - control with Supplemental Dose). A single dose of c7vPnC will be administered after the Prevnar 13 series is completed in this group.

Read More about Pfizer Infant Vaccine Study C3571002

This is a phase 1, open-label, single-dose, multicenter study to determine the PK, safety, and tolerability of IV eravacycline in children 8 to <18 years of age with suspected or confirmed bacterial infection who are receiving systemic antibiotic therapy, other than eravacycline. Eravacycline will be administered as a single IV dose using the optimum dosage determined from PK/pharmacodynamic (PD) modeling and -model-based simulations of phase 1, 2, and 3 adult data. Blood samples will be collected for PK analysis at predetermined timepoints (see PK Assessments).

Read More about A Phase 1, Open-label, Multicenter Study to Determine the Pharmacokinetics and Safety of Intravenous Eravacycline in Children with Suspected or Confirmed Bacterial Infection

Comparing open surgical bypass to endovascular therapy in CLI patients with a composite clinical endpoint denoted as Major Adverse Limb Event free survival (MALE-free survival). MALE-free survival captures major clinical limb-events (above ankle amputation, need for repeat bypass, interposition graft, thrombectomy, thrombolysis), and death. However the BEST CLI trial does not capture bypass or stent failure as it does not mandate surveillance duplex ultrasonography.

Read More about The Impact of Diabetes on REvascularization in BEST-CLI (TIDE)

To understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for ICD therapy. The incidence of all-cause shocks in subjects programmed with shocks only will be compared with subjects programmed to standard therapy (ATP and shock) to assess equivalency.

Multivariate analyses will also be performed to determine which baseline clinical factors are associated with the use of ATP, bradycardia pacing, and the need for CRT-D pacing therapy.

Read More about Assessment of Primary Prevention Patients Receiving An Animplantable Cardioverter Defibrillator (ICD) – Systematic Evaluation of ATP (APPRAISE ATP)

To assess the effect of a customized, multifaceted, health system-level QI program compared with usual care on HF outcomes (i.e., composite of HF readmissions or all-cause mortality) and HF quality metrics (i.e., as assessed by an opportunity-based composite score) in the year following discharge for participants with acute HF and reduced left ventricular ejection fraction(LVEF)

Read More about Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure - CONNECT - HF

To describe the population pharmacokinetics of high-dose parenteral acyclovir (60 mg/kg/day) in neonates with virologically confirmed neonatal HSV disease and who are receiving acyclovir as standard of care.

Read More about An observational study of Acyclovir Pharmacokinetics, viral population kinetics, and potential biomarkers of disease severity in neonatal herpes simplex virus infections

To determine the efficacy of AMAG-423 for the prevention of intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), or death in the offspring of women with severe preeclampsia

Read More about A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Preeclampsia

To prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity including respiratory distress syndrome in pregnant women with a singleton gestation between 24w0d to 32w6d gestation who have documented premature rupture of the membranes.

Read More about A Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids on Neonatal Outcome in Patients with Pre-labor Premature Rupture of Membranes

The study objective is to demonstrate that the 6-month cumulative patency of grafts connected with the InterGraft™ VIG connectors is similar to that of grafts connected using standard sutured anastomoses.

Read More about Clinical Evaluation of a Vascular Venous Anastomotic Connector for Minimally Invasive Connection of an Arteriovenous Graft for Hemodialysis [InterGraft™ Study]

Clinical Trials